Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control (Q35895868)

11 August 2017

Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose control (English)

1 reference

11 August 2017

B Ahrén

1

1 reference

PubMed ID

26774018

11 August 2017

language of work or name

1 reference

1 December 2015

1 reference

11 August 2017

Diabetes and Metabolism

1 reference

11 August 2017

41

1 reference

11 August 2017

6S3-6S8

1 reference

11 August 2017

6 Suppl 1

1 reference

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Molecular basis of insulin action

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Insulin within islets is a physiologic glucagon release inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Effects of glucagon-like peptide 1 on the hepatic glucose metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Direct effect of GLP-1 infusion on endogenous glucose production in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Hepato-incretin function of GLP-1: novel concept and target in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with typ

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

GLP-1 for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

'Glucose control-related' and 'non-glucose control-related' effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

beta-cell failure in diabetes and preservation by clinical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2816%2930002-7

7 January 2021

10.1016/S1262-3636(16)30002-7

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

26774018